All Stories

  1. The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2019, Taylor & Francis

    Dr Keisuke Tomii, David Lipson

  2. The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time

    Article • September 2019, European Respiratory Society (ERS)

    David Lipson

  3. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, September 2018, Taylor & Francis

    Dr Aik H Goh, David Lipson, Jinping Zheng

  4. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

    Article • American Review of Respiratory Disease, August 2017, American Thoracic Society

    David Lipson